In particular, we have previously reported the importance of inhibiting the pathological POSTN splicing variant with exon 21 (PN1-2) in chemotherapy-resistant breast cancer, malignant melanoma, diabetic retinopathy, inflammatory bowel disease, atherosclerosis, aortic aneurysm, etc. [14,15,16]. This evidence concerns the gene POSTN and breast cancer.